Widely recognized as a major marker of neuroendocrine tumor (NET), chromogranin A (CgA) has been found to be related to the clinical deterioration and higher risk of mortality in patients with AHF and CHF [102]. The gene discussed is CHGA; the disease is neuroendocrine neoplasm.